EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice

Osamu Kikuchi, Yuichi Ikeuchi, Masaki Kobayashi, Yoko Tabei, Hiromi Yokota-Hashimoto, Tadahiro Kitamura iD

Journal of Diabetes Investigation · 2024

DOI: 10.1111/jdi.14249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2024. Verfasst von Osamu Kikuchi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan. Hauptthemen laut MEDLINE: Diet, High-Fat, Glucagon, Fatty Liver. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sumitomo Pharma Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction Imeglimin is a recently approved oral antidiabetic agent that improves insulin resistance, and promotes insulin secretion from pancreatic β‐cells. Here, we investigated the effects of imeglimin on glucagon secretion from pancreatic α‐cells. Materials and Methods Experiments were carried out in high‐fat, high‐sucrose diet‐fed mice. The effects of imeglimin were examined using insulin and glucose tolerance tests, glucose clamp studies, and measurements of glucagon secretion from isolated islets. Glucagon was measured using both the standard and the sequential protocol of Mercodia sandwich enzyme‐linked immunosorbent assay; the latter eliminates cross‐reactivities with other proglucagon‐derived peptides.

Results

Plasma glucagon, insulin and glucagon‐like peptide‐1 levels were increased by imeglimin administration in high‐fat, high‐sucrose diet‐fed mice. Glucose clamp experiments showed that the glucagon increase was not caused by reduced blood glucose levels. After both single and long‐term administration of imeglimin, glucagon secretions were significantly enhanced during glucose tolerance tests. Milder enhancement was observed when using the sequential protocol. Long‐term administration of imeglimin did not alter α‐cell mass. Intraperitoneal imeglimin administration did not affect glucagon secretion, despite significantly decreased blood glucose levels. Imeglimin did not enhance glucagon secretion from isolated islets. Imeglimin administration improved fatty liver by suppressing de novo lipogenesis through decreasing sterol regulatory element binding protein‐1c and carbohydrate response element binding protein and their target genes, while enhancing fatty acid oxidation through increasing carnitine palmitoyltransferase I.

Conclusions

Overall, the present results showed that imeglimin enhances glucagon secretion through an indirect mechanism. Our findings also showed that glucagon secretion promoted by imeglimin could contribute to improvement of fatty liver through suppressing de novo lipogenesis and enhancing fatty acid oxidation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, High-FatGlucagonFatty LiverAnimalsMiceMaleMice, Inbred C57BLInsulinBlood GlucoseGlucagon-Secreting CellsGlucose Tolerance TestGlucagon-Like Peptide 1Dietary SucroseHypoglycemic AgentsInsulin ResistanceTriazines

Stichwörter der Autor:innen

GlucagonGlucagon‐like peptide‐1Imeglimin

Substanzen

GlucagonimegliminInsulinBlood GlucoseGlucagon-Like Peptide 1Dietary SucroseHypoglycemic AgentsTriazines

Autor:innen und Institutionen

  • Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan.

ORCID-Profile: Tadahiro Kitamura

Förderung

  • Sumitomo Pharma Co., Ltd.

Zitieren

APA

Kikuchi, O., Ikeuchi, Y., Kobayashi, M., Tabei, Y., Yokota-Hashimoto, H., & Kitamura, T. (2024). Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14249

Vancouver

Kikuchi O, Ikeuchi Y, Kobayashi M, Tabei Y, Yokota-Hashimoto H, Kitamura T. Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14249

BibTeX
@article{Kikuchi2024,
  author = {Kikuchi, Osamu and Ikeuchi, Yuichi and Kobayashi, Masaki and Tabei, Yoko and Yokota-Hashimoto, Hiromi and Kitamura, Tadahiro},
  title = {Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  doi = {10.1111/jdi.14249}
}
Kostenlos starten →